ITM to Present Pancreatic Neuroendocrine Tumor Subgroup Analysis from Phase 3 COMPETE Trial at ENETS 2026
核心洞察
ITM Isotope Technologies Munich will present post-hoc subgroup analysis data focusing on pancreatic neuroendocrine tumors from its Phase 3 COMPETE trial at the 23rd Annual ENETS Conference in March 2026.
The COMPETE trial successfully met its primary endpoint, demonstrating that 177Lu-edotreotide achieved clinically and statistically significant improvement in progression-free survival compared to everolimus in patients with gastroenteropancreatic neuroendocrine tumors.
The company will also host an interactive symposium bringing together leading experts in radiopharmaceutical oncology to discuss key challenges and emerging clinical approaches for neuroendocrine tumor treatment.
ITM Isotope Technologies Munich SE announced it will present additional exploratory and post-hoc subgroup analysis data from its Phase 3 COMPETE trial, specifically focusing on pancreatic neuroendocrine tumors, at the 23rd Annual European Neuroendocrine Tumor Society (ENETS) Conference in Kraków, Poland, from March 4-6, 2026.
Conference Presentation Details
Prof. Dr. Thomas Walter, a medical oncologist from Lyon, France, will deliver the oral presentation titled "177Lu-edotreotide for the Treatment of Pancreatic Neuroendocrine Tumours: A Subgroup Analysis from the COMPETE Study" on Thursday, March 5, from 11:50-11:57 AM (CET) at Theatre Hall S2 in the ICE Kraków Congress Centre.
The company will also host an interactive satellite symposium titled "Vote and Learn: Radiopharmaceutical Therapy in NETs" on March 5 from 07:45-08:45 AM (CET). The symposium will feature presentations from Dr. Francesca Spada, a medical oncologist from Milano, Italy; Prof. Christophe Deroose, a nuclear medicine physician from Leuven, Belgium; and Prof. Simron Singh, a medical oncologist from Toronto, Canada.
COMPETE Trial Results
The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), ITM's proprietary synthetic targeted radiotherapeutic investigational agent, compared to everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial successfully met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival compared to everolimus.
Regulatory Status and Future Development
177Lu-edotreotide remains an investigational product pending review by the U.S. Food and Drug Administration and has not received approval from any regulatory authority for safety and efficacy of any intended use. The compound is also being evaluated in COMPOSE, a Phase 3 study examining its efficacy in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NET tumors.
Company Background
ITM positions itself as a leading radiopharmaceutical biotech company dedicated to developing next-generation radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company advances a broad precision oncology pipeline that includes multiple Phase 3 studies, combining high-quality radioisotopes with various targeting molecules. With two decades of radiopharmaceutical expertise, ITM aims to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.